| Předmět: |
|
| Zdroj: |
Biomedical Market Newsletter; 3/28/2012, Vol. 21, p1-4, 4p |
| Abstrakt: |
The article provides information on the release of results from the TRA-2P (Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events) TIMI 50 study of vorapaxar. The study has been designed to evaluate the efficacy of vorapaxer in treating patients with a prior history of cardiovascular events or disease. The results indicated that vorapaxar significantly reduces the risk of composite of cardiovascular (CV) death, heart attack and stroke. |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
